# City Therapeutics Inc. (CTY)

Source: https://www.quantisnow.com/company/CTY
Generated: 2026-11-10T19:30:47.533Z

- Ticker: CTY
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2026
- SEC CIK: 0002143850

## About

City Therapeutics is a clinical-stage biotechnology company engineering the next generation of RNA interference (RNAi) therapeutics, with the aim of delivering meaningful and durable benefits for patients in need. City's lead development programs are CITY-FXI for thromboembolic diseases, CITY-RBP4 for Stargardt disease and other retinal diseases, and CITY-TFR2 for anemia associated with chronic diseases. The City Platform is the engine behind every therapeutic the company develops and integrates deep expertise in trigger engineering, including proprietary cityRNA triggers designed to address limitations of conventional RNAi approaches, tissue-selective delivery, and genetics-driven target selection.

## Latest CTY news and filings

- 2026-11-10 13:38 UTC [Analyst Coverage Initiated] [Oppenheimer initiated coverage on City Therapeutics with a new price target](https://www.quantisnow.com/insight/oppenheimer-initiated-coverage-on-city-therapeutics-with-a-new-price-6783181)
- 2026-11-10 12:34 UTC [Analyst Coverage Initiated] [Stifel initiated coverage on City Therapeutics with a new price target](https://www.quantisnow.com/insight/stifel-initiated-coverage-on-city-therapeutics-with-a-new-price-6782872)
- 2026-11-10 12:34 UTC [Analyst Coverage Initiated] [Jefferies initiated coverage on City Therapeutics with a new price target](https://www.quantisnow.com/insight/jefferies-initiated-coverage-on-city-therapeutics-with-a-new-price-6782871)
- 2026-11-10 12:06 UTC [SEC Form 8-K] [City Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/city-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6782764)
- 2026-11-10 12:00 UTC [Public Offering] [City Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of CITY-RBP4 for the Treatment of Stargardt Disease](https://www.quantisnow.com/insight/city-therapeutics-announces-first-participant-dosed-in-phase-1-clinical-6782692)
- 2026-11-06 14:46 UTC [SEC Schedule 13G] [SEC Form SCHEDULE 13G filed by City Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-city-therapeutics-inc-6778321)
- 2026-11-04 14:01 UTC [Phase 1 Data for CITY-FXI, an RNAi Therapeutic Candidate for Thromboembolic Diseases, Selected for Oral Presentation at the 68th ASH Annual Meeting](https://www.quantisnow.com/insight/phase-1-data-for-city-fxi-an-rnai-therapeutic-candidate-for-6771690)
- 2026-11-03 13:00 UTC [Conference Announcement] [City Therapeutics to Present at Upcoming November Investor Conferences](https://www.quantisnow.com/insight/city-therapeutics-to-present-at-upcoming-november-investor-conferences-6768498)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/CTY
- Earnings history: https://www.quantisnow.com/earnings/CTY
- Dividend history: https://www.quantisnow.com/dividends/CTY
- Insider transactions: https://www.quantisnow.com/insiders/CTY
- Options chain: https://www.quantisnow.com/options/CTY
- SEC 8-K filings only: https://www.quantisnow.com/company/CTY/8-k
- RSS and alerts for CTY: https://www.quantisnow.com/docs/rss-feeds.md